Clinical Trials Browser

Has results × eribulin × Gastrointestinal × Clear all

NCT00383760 2017-10-20

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Phase 2 Completed

15 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms